A finger prick instead of a needle: could At-Home blood tests match hospital accuracy?

NCT ID NCT07802665

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 03, 2026 · Last updated Sep 04, 2026 · Updated 1 time

Summary

This study tests whether blood samples collected at home using small capillary devices, like finger pricks, give the same results as traditional blood draws from a vein. Researchers will compare both methods in about 1,000 people with chronic conditions such as kidney disease, autoimmune disorders, or who have had organ transplants. Some participants will also collect a sample at home and mail it in to see if postal delays or temperature changes affect accuracy. The goal is to find out which blood tests can be safely monitored without a hospital visit.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Capillary blood sampling devices for self-collection of blood samples
What this could lead to
If successful, this could enable reliable at-home blood monitoring for many chronic conditions, reducing hospital visits and making care more accessible.
What could go wrong
The trial is observational and compares test accuracy; results may show that some blood tests are not reliable with home collection, and the study does not test treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 1,000 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2026

An estimate. Start dates often move.

Expected to finish

Sep 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

A maximum of 1000 participants will be recruited. The study aims to include approximately 200 participants from each of five clinical populations in which regular blood monitoring forms part of routine care and where remote capillary blood sampling has the potential to improve access to monitoring or patient experience: * Patients with kidney disease * Patients with immune-mediated disease * Kidney, kidney-pancreas and islet transplant recipients * Patients with mental health disorders requiring regular blood monitoring * Children attending paediatric services who require regular blood monitoring

Ages

6 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Eligible participants are individuals who require routine venous blood sampling as part of their usual clinical care and who represent clinical populations in which remote capillary blood sampling may improve access to monitoring or patient experience. All participants must: * Be attending a routine clinical appointment during which venous blood sampling is planned as part of standard clinical care for disease monitoring or therapeutic drug monitoring. * Be willing and able to undertake capillary blood sampling independently or with appropriate assistance. Adult participants must: * Be aged ≥18 years of age. * Have capacity to provide written informed consent. Paediatric participants must: * Be aged 6-15 years of age. * If aged 6-11, be attending with a parent or legal guardian able to provide written informed consent and provide age-appropriate assent where applicable. * If aged 12-15: be attending with a parent or legal guardian able to provide written informed consent and provide age-appropriate assent where applicable OR if deemed to have capacity themselves, be able to provide written informed consent and be attending with a parent or legal guardian who agrees to their participation. Additional eligibility criteria Autoimmune disease group: participants must have a diagnosis of immune-mediated disease based on the assessment of their treating clinician. Transplant recipient group: participants must be the recipient of a functioning kidney, kidney-pancreas, or islet transplant. Mental health group: participants must have a diagnosis of a mental health disorder based on the assessment of their treating clinician. Paediatric group: participants must be attending a paediatric clinic and require blood sampling as part of standard clinical care. Exclusion Criteria: * Inability or unwillingness to provide informed consent, or, for paediatric participants, absence of parental or legal guardian consent or age-appropriate assent where applicable. * Skin disease, infection, injury, or other local factors at the intended sampling site that would make capillary blood collection unsafe or impractical. * Known allergy or hypersensitivity to any materials used in the capillary blood sampling devices. * Inability to undertake the capillary sampling procedures independently or with appropriate assistance.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Autoimmune diseases are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.